Author(s): Rezlie Bellatasie, Suharjono Suharjono, Wiwid Samsulhadi, Nur Palestin Ayumuyas

Email(s): suharjono@ff.unair.ac.id

DOI: 10.52711/0974-360X.2022.00689   

Address: Rezlie Bellatasie1,2, , Suharjono Suharjono3*, Wiwid Samsulhadi4, Nur Palestin Ayumuyas5
1Master of Clinical Pharmacy Program, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
2Department of Pharmacology and Clinical Pharmacy, School of Pharmaceutical Sciences, Padang, Indonesia.
3Department of Pharmacy Practice, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
4Department of Internal Medicine, Surabaya Hajj General Hospital, Surabaya, Indonesia.
5Department of Hospital Pharmacy, Surabaya Hajj General Hospital, Surabaya, Indonesia.
*Corresponding Author

Published In:   Volume - 15,      Issue - 9,     Year - 2022


ABSTRACT:
Inflammation is the underlying cause of several comorbid diseases, including macrovascular complications that cause the highest mortality in diabetes patients. One of the pro-inflammatory cytokines used to assess inflammatory conditions in diabetes and its complications is IL-6. This study intends to analyze the effect of atorvastatin administration on lipid profile and inflammatory markers after 30 days and the correlation between lipid profile and IL-6. An observational prospective cohort study was conducted from November 2017 to January 2018 and approved by the ethical committee of General Hajj Hospital, Surabaya. Nineteen patients who met the inclusion criteria and signed the informed consent enrolled in this study. The measurement of lipid profile and IL-6 level were done twice, before and after 30 days of atorvastatin therapy. After atorvastatin administration, there was a 40.55% decrease in LDL level, a 15.34% decrease in TG level, a 30.70% decrease in total cholesterol level, which was statistically significant (p<0.05), and a 6.06% increase in HDL level. There was a 5.76% decrease in the IL-6 level (p>0.05). In conclusion, atorvastatin administration can improve lipid profile in diabetes patients with dyslipidemia. There was a decrease in IL-6 but not statistically different. From statistical analysis, there is no correlation found between lipid profile and IL-6


Cite this article:
Rezlie Bellatasie, Suharjono Suharjono, Wiwid Samsulhadi, Nur Palestin Ayumuyas. The Effect of Atorvastatin on Lipid Profile and Inflammatory Marker in patient with Diabetes Dyslipidemia. Research Journal of Pharmacy and Technology. 2022; 15(9):4105-0. doi: 10.52711/0974-360X.2022.00689

Cite(Electronic):
Rezlie Bellatasie, Suharjono Suharjono, Wiwid Samsulhadi, Nur Palestin Ayumuyas. The Effect of Atorvastatin on Lipid Profile and Inflammatory Marker in patient with Diabetes Dyslipidemia. Research Journal of Pharmacy and Technology. 2022; 15(9):4105-0. doi: 10.52711/0974-360X.2022.00689   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-9-49


REFERENCES:
1.    Powers AC. Diabetes Mellitus: Diagnosis, Classification, and Pathophysiology. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw Hill Education; 2015.
2.    Dipiro JT, Talbert GC., Yee GR., Matzke BG., Wells LMP. Pharmacotherapy: A Pathophysiology Approach, 10th Edition. In: DiPiro JT, Talbert RI, Yee GC, Matzke GR, Wells BG, Posey IM, editors. Mc-Graw Hill Medical. 10th ed. The McGraw-Hill Companies; 2017. p. 6007–48.
3.    International Diabetes Federation. Diabetes Atlas [Internet]. 7th ed. Cavan, David; Fernandez, Joao da Rocha; Makaroff, Lydia; Ogurtsova, Katherine; Webber S, editor. Vol. 102, Diabetes Research and Clinical Practice. Brussel; 2015. Available from: www.diabetesatlas.org
4.    American Diabetes Association. Standards of medical care in diabetes-2017. Cefalu WT, editor. Vol. 40, Diabetes Care. 2017. 1–142 p.
5.    de Souza Bastos A, Graves DT, de Melo Loureiro AP, Júnior CR, Corbi SCT, Frizzera F, et al. Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients. J Dia Comp. 2016;30(8):1593–9.
6.    Wang CCL, Hess CN, Hiatt WR, Goldfine AB. Clinical update: Cardiovascular disease in diabetes mellitus. Circulation. 2016;133(24):2459–502.
7.    Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: Prevalence, pathophysiology, and management. Drugs. 2013;73(4):327–39.
8.    PERKENI. Konsensus Pengelolaan dan Pencegahan Diabetes Mellitus Tipe 2 di Indonesia 2015. Pb Perkeni. 2015. 1–93 p.
9.    Brunton LL, Chabner BA, Knollman BC, editors. Drug Therapy for Hypercholesterolemia and Dyslipidemia. In: Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 12th ed. California: The McGraw-Hill Companies; 2010.
10.    Rosenson RS. Statins: Actions, side effects, and administration [Internet]. Wolter Kluwers. 2016 [cited 2006 Jun 20]. p. 1–26. Available from: www.uptodate.com
11.    Zhao J, Zhang X, Dong L, Wen Y, Cui L. The Many Roles of Statins in Ischemic Stroke. Curr Neuropharmacol. 2014;12(6):564–74.
12.    Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017;120(1):229–43.
13.    Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (Pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46(8):1425–33.
14.    Mihos CG, Pineda AM, Santana O. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res. 2014;88:12–9.
15.    Tousoulis D, Papageorgiou N, Androulakis E, Siasos G, Latsios G, Tentolouris K, et al. Diabetes mellitus-associated vascular impairment: Novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013;62(8):667–76.
16.    Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection. Circ Res. 2016;118(1):145–56.
17.    Haidari F, Mansoori E, Zakerkish M, Haghighizadeh M. The relationship between metabolic factors and quality of life aspects in type 2 diabetes patients. Res J Pharm Technol. 2017;10(5):1491–6.
18.    Jeeva S, Babu M. Knowledge of Diabetic Clients Regarding Self-care Practices in Management of type II Diabetes Mellitus at selected Rural Community of Bangalore, Karnataka. Asian J Nurs Educ Res. 2017;7(1):86.
19.    Mohsen H, Shaden H, Faiza AQ, Taghrid H. Correlation of serum leptin levels with insulin resistance in Syrian obese patients with type 2 diabetes mellitus. Res J Pharm Technol. 2013;6(10):1149–51.
20.    Panari H, Vegunarani M. Study on Complications of Diabetes Mellitus among the Diabetic Patients. Asian J Nurs Educ Res. 2016;6(2):171.
21.    Raphael M, Vijayanarayana K, Thunga G, Karthik Rao N, Sreedharan N. Utilization pattern of anti-diabetic drugs in type 2 diabetes mellitus in tertiary care hospital. Res J Pharm Technol. 2017;10(7):2063–8.
22.    Sangeeta M, Raghavendra NS. A Study to assess the effectiveness of Planned Teaching Programme on knowledge regarding self care behaviour among people suffering from Diabetes Mellitus in selected urban health centres of Belgavi. Int J Nurs Educ Res. 2019;7(3):399.
23.    Geetha V, Sahu SK, Susila C. Assess Quality of Life (QOL) and Glycemic Level among Type 2 Diabetic Patients in Global Hospital and Research Centre and its Units, Sirohi, Rajasthan. Asian J Nurs Educ Res. 2017;7(4):577.
24.    Kementrian Kesehatan. Situasi dan Analisis Diabetes [Internet]. 2014 [cited 2006 Jul 20]. Available from: www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-diabetes.pdf
25.    Mihardja L, Soetrisno U, Soegondo S. Prevalence and clinical profile of diabetes mellitus in productive aged urban Indonesians. J Diabetes Invest. 2014;5(5):507–12.
26.    Acharya LD, Rau NR, Udupa N, Surulivel RM, Vijayanarayana K. Trends in prescribing antihypertensive medications and lipid lowering therapy in type-2 diabetic patients in south Indian tertiary care hospital. Res J Pharm Technol. 2016;9(7):857–63.
27.    Ranadheer Chowdary P, Praveen D, Vijey Aanandhi M. A prospective study on incidence of dyslipidemia in diabetes mellitus. Res J Pharm Technol. 2017;10(2):431–3.
28.    Mounika V, Sarumathy S, Anisha Ebens J, Shanmugarajan TS. A prospective study on incidence of anaemia in type 2 diabetes mellitus patients. Res J Pharm Technol. 2017;10(1):11–4.
29.    Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, et al. Obesity and type 2 diabetes: What Can be unified and what needs to be individualized? Diabetes Care. 2011;34(6):1424–30.
30.    Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2013;129(25 SUPPL. 1). Available from: https://www.ahajournals.org/doi/suppl/10.1161/01.cir.0000437738.63853.7a
31.    Parsa P, Ahmadinia-Tabesh R, Mohammadi Y. Assessment of the risk of Coronary Heart Disease in Diabetes Patients Type-II. Asian J Nurs Educ Res. 2019;9(2):267.
32.    Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol. 2005;19(1):117–25.
33.    Lacy C, Armstrong L, Goldman M, Lance L. Drug Information Handbook. 24th ed. New York: Lexicomp; 2016.
34.    Anderson N, Tobin JN, Zazula T. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel. NIH. 2002.
35.    AHFS. AHFS Drug Information Essentials. McEvoy GK, editor. Maryland: American Society of Health-System Pharmacists; 2011.
36.    Mukti AW, Suprapti B, Wibisono S. Effect of atorvastatin treatment on vascular aterogenic factors (LipiD profiles and VCAM-1) in patient diabetes with dyslipidemia. Indones J Pharm. 2019;30(2):128–32.
37.    Dorotea D, Ayumuyas NP, Suprapti B, Wibisono S. The Comparison of Simvastatin and Atorvastatin Efficacy in Lowering Lipid Profile and Apolipoprotein-B of Diabetic Dyslipidemia Patient. FMI. 2013;49(3):139–45.
38.    Deerochanawong C, Buranakitjaroen P, Nitiyanant W, Suwantamee J, Piamsomboon C, Vongthavaravat V, et al. The atorvastatin goal achievement across risk levels: (ATGOAL) study in Thailand. J Med Assoc Thail. 2007;90(1):72–81.
39.    McKenney JM, Davidson MH, Saponaro J, Thompson PD, Bays HE. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005;46(5):594–9.
40.    Geiss HC, Otto C, Schwandt P, Parhofer KG. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism. 2001;50(8):983–8.
41.    Parhofer KG, Laubach E, Barrett PHR. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J Lipid Res. 2003;44(6):1192–8.
42.    Rosales A, Alvear M, Cuevas A, Saavedra N, Zambrano T, Salazar LA. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Clin Chim Acta. 2012;413(3–4):495–501.
43.    Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: Insights from therapeutic interventions. J Am Coll Cardiol. 2005;46(11):1978–85.
44.    Biasucci LM, Biasillo G, Stefanelli A. Inflammatory markers, cholesterol and statins: Pathophysiological role and clinical importance. Clin Chem Lab Med. 2010;48(12):1685–91.
45.    Kanat M, Özcan Y, Tunçkale A, Ceyhan BÖ, Karagoz Y, Altuntas Y, et al. Intensive Lipid Reduction and Proinflammatory Markers in the MODEST Study. Turk Jem. 2010;14:31–4.
46.    Nazari A, Sardoo AM, Fard ET. Is IL-6 Increased in Type 2 Diabetes Mellitus Patients Independent of Nephropathic Complication ? J Endocrinol Diabetes Obes. 2017;5:10–2.
47.    Aziz N, Detels R, Quint JJ, Li Q, Gjertson D, Butch AW, et al. Stability of cytokines, chemokines and soluble activation markers in unprocessed blood stored under different conditions. Cytokine. 2016;84:17–24.
48.    Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway. J Gerontol A Biol Sci Med Sci. 2006;61(6):575–84.
49.    Belalcazar LM, Haffner SM, Lang W, Hoogeveen RC, Rushing J, Schwenke DC, et al. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: From the look AHEAD study. Obesity. 2013;21(5):944–50.
50.    Bochar O, Sklyarov E, Bochar V. Leptin and interleukin-6 level in patients with hypertension and obesity combined with non-alcoholic steatohepatitis during treatment with Sartans and Statins. Curr Issues Pharm Med Sci. 2017;30(2):57–60.
51.    Kyrsiak R, Gdula-Dymek A, Marek B, Okopien B. The effect of hypolipidaemic treatment on monocyte release of proinflammatory cytokines in different age groups of patients with type 2 diabetes and atherogenic dyslipidaemia. Endokrynol Pol [Internet]. 2013;62(2):190–6. Available from: age; simvastatin; fenofibrate; atherogenic dyslipidaemia; monocytes; cytokines
52.    Mavridis G, Souliou E, Diza E, Symeonidis G, Pastore F, Vassiliou AM, et al. Inflammatory cytokines in insulin-treated patients with type 2 diabetes. Nut Metab Cardiovas. 2008;18(7):471–6.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available